A
AbbVie Inc. (ABBV)
NYQ – Real vaqt narxi. Valyuta: USD
207.86
+5.08 (2.51%)
Yopilishda: May 12, 2026, 4:01 PM EDT
208.28
+0.42 (0.20%)
Bozordan keyin: May 12, 2026, 8:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
207.86
+5.08 (2.51%)
Yopilishda: May 12, 2026, 4:01 PM EDT
208.28
+0.42 (0.20%)
Bozordan keyin: May 12, 2026, 8:00 PM EDT
AbbVie Inc., tadqiqotga asoslangan biofarmatsevtika kompaniyasi, dunyo bo'ylab dori vositalari va terapiyalarni tadqiq qilish va ishlab chiqish, ishlab chiqarish, tijoratlashtirish va sotish bilan shug'ullanadi. Kompaniya autoimmun kasalliklarini davolash uchun Skyrizi; yallig'lanish kasalliklarini davolash uchun Rinvoq; qon saratoni bilan og'rigan kattalar bemorlarini davolash uchun Imbruvica; qon saratonini davolash uchun Venclexta; turli xil saratonlarni davolash uchun Elahere; limfomani davolash uchun Epkinly; va o'pka saratonini davolash uchun Emrelisni taklif etadi. Shuningdek, u yuz uchun in'ektsiyalar, plastika va regenerativ tibbiyot, tana konturlash va terini parvarish qilish mahsulotlarini; glabellar chiziqlari, qarg'a oyoqlari, peshonadagi chiziqlar va platysma bantlarini davolash uchun Botox Cosmeticni; peshonadagi, ko'z ostidagi, yonoqlardagi, iyakdagi, lablardagi va yuzning pastki qismidagi hajmni yo'qotishni davolash uchun Juvederm Kolleksiyasini; shizofreniya, bipolyar buzuqlik va depressiv buzuqlikni davolash uchun Vraylar; Parkinson kasalligini davolash uchun Duodopa; migrenni davolash uchun Ubrelvy; epizodik va surunkali migren uchun Qulipta; va harakatlanishning o'zgarishlarini davolash uchun Vyalev, shuningdek surunkali migren, giperaktiv siydik pufagi, spastiklik, bachadon distoniyasi va boshqa sharoitlarni davolash uchun Botox Therapeuticni taqdim etadi. Bundan tashqari, kompaniya ko'rishning buzilishlari uchun Ozurdex; ochiq burchakli glaukoma yoki ko'z gipertenziyasi bo'lgan bemorlarda ko'z ichidagi bosimni pasaytirish uchun Lumigan/Ganfort va Alphagan/Combigan; va Refresh/Optive, Xen, Durysta va Restasis kabi boshqa ko'z parvarishi mahsulotlarini taklif etadi. Shuningdek, u A gepatit virusi 1-6 genotiplari bilan surunkali infektsiyani davolash uchun Mavyret; oshqozon osti bezi ferment terapiyasi bo'lgan Creon; va ich qotishi bilan bezovta ichak sindromi va surunkali idiyopatik ich qotishini davolash uchun Linzess/Constella ni taqdim etadi. Kompaniya 2012 yilda ro'yxatga olingan va Illinoys shtatining North Chicago shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO |
| Dr. Nicholas J. Donoghoe M.D. | Executive VP and Chief Business & Strategy Officer |
| Dr. Roopal B. Thakkar M.D. | Executive VP of Research & Development and Chief Scientific Officer |
| Mr. Demetris D. Crum | Executive VP & Chief Human Resources Officer |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary |
| Mr. Scott T. Reents | Executive VP & CFO |
| Mr. Wulff-Erik von Borcke | Senior VP & President of Oncology |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations |
| Ms. Linda Ray | Senior VP & Chief Information Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 10-Q | abbv-20260331.htm |
| 2026-04-29 | 8-K | abbv-20260429.htm |
| 2026-04-03 | 8-K | abbv-20260403.htm |
| 2026-03-23 | DEFA14A | abbv-20260323xdefa14a.htm |
| 2026-03-23 | DEF 14A | abbv-20260508xdef14a.htm |
| 2026-03-09 | PRE 14A | abbv-20260309xpre14a.htm |
| 2026-03-04 | 8-K | tm266774d4_8k.htm |
| 2026-02-20 | 10-K | abbv-20251231.htm |
| 2026-02-04 | 8-K | abbv-20260204.htm |
| 2026-01-07 | 8-K | abbv-20260107.htm |